The pleiotropic effects of statins in the prevention of atherosclerosis: Editorial to: "simvastatin suppresses apoptosis in vulnerable atherosclerotic plaques through regulating the expression of p53, Bcl-2 en Bcl-xL" by Weiwei Qin et al.

Cardiovascular Drugs and Therapy

Volumn 26, Issue 1, 2012, Pages 5-7

  Kong, Wei ^a   Zhu, Yi ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ADVANCED GLYCATION END PRODUCT RECEPTOR; C REACTIVE PROTEIN; CERIVASTATIN; CHOLESTEROL; CYTOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GELATINASE A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MATRIX METALLOPROTEINASE; MEVALONIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; THROMBOPLASTIN; VASCULAR CELL ADHESION MOLECULE 1;

ADVERSE OUTCOME; APOPTOSIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CELL COUNT; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE CONTROL; DISEASE COURSE; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; EDITORIAL; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME METABOLISM; HUMAN; HYPERCHOLESTEROLEMIA; LIPID STORAGE; MACROPHAGE; MORBIDITY; MORTALITY; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; RISK REDUCTION; SMOOTH MUSCLE FIBER; THROMBOCYTE AGGREGATION INHIBITION; VASCULAR SMOOTH MUSCLE; VASCULITIS; VASOCONSTRICTION;

ANIMALS; APOPTOSIS; ATHEROSCLEROSIS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PLAQUE, ATHEROSCLEROTIC; SIMVASTATIN;

EID: 84857790486     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-011-6353-1     Document Type: Editorial

References (30)

1. AW Alberts J Chen G Kuron, et al. 1980 Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent Proc Natl Acad Sci USA 77 3957 3961 6933445 10.1073/pnas.77.7.3957 1:CAS:528:DyaL3cXlvFOlurk%3D (Pubitemid 10015499)
2. AW Alberts 1988 Discovery, biochemistry and biology of lovastatin Am J Cardiol 62 10J 15J 3055919 10.1016/0002-9149(88)90002-1 1:CAS:528: DyaL1MXjtlajug%3D%3D (Pubitemid 18263851)
3. ES Istvan J Deisenhofer 2001 Structural mechanism for statin inhibition of HMG-CoA reductase Science 292 1160 1164 11349148 10.1126/science.1059344 1:CAS:528:DC%2BD3MXjs1Cgtbo%3D (Pubitemid 32440937)
4. Group Heart Protection Study Collaborative 2002 MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 7 22 10.1016/S0140-6736(02) 09327-3 (Pubitemid 34756487)
5. K Almuti R Rimawi D Spevack, et al. 2006 Effects of statins beyond lipid lowering: potential for clinical benefits Int J Cardiol 109 7 15 16054715 10.1016/j.ijcard.2005.05.056
6. JK Liao 2005 Clinical implications for statin pleiotropy Curr Opin Lipidol 16 624 629 16276239 10.1097/01.mol.0000191913.16321.60 1:CAS:528:DC%2BD2MXhtFymtb%2FL (Pubitemid 43012159)
7. CG Mihos MJ Salas O Santana 2010 The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review Cardiol Rev 18 298 304 20926939 10.1097/CRD. 0b013e3181f52a7f
8. Q Zhou JK Liao 2010 Pleiotropic effects of statins.-basic research and clinical perspectives Circ J. 74 818 826 20424337 10.1253/circj.CJ-10-0110 1:CAS:528:DC%2BC3cXms1ajsbw%3D
9. B Sadowitz KG Maier V Gahtan 2010 Basic science review: statin therapy-Part I: the pleiotropic effects of statins in cardiovascular disease Vasc Endovasc Surg. 44 241 251 10.1177/1538574410362922
10. JL Goldstein MS Brown 1990 Regulation of the mevalonate pathway Nature 343 425 430 1967820 10.1038/343425a0 1:CAS:528:DyaK3cXhtlCmtbw%3D (Pubitemid 20065229)
11. L Van Aelst C D'Souza-Schorey 1997 Rho GTPases and signaling networks Genes Dev 11 2295 2322 9308960 10.1101/gad.11.18.2295 (Pubitemid 27408529)
12. A Hall 1998 G proteins and small GTPases: distant relatives keep in touch Science 280 2074 2075 9669963 10.1126/science.280.5372.2074 1:CAS:528:DyaK1cXkt1Ggsrw%3D (Pubitemid 28366192)
13. P Adamson CJ Marshall A Hall PA Tilbrook 1992 Post-translational modifications of p21rho proteins J Biol Chem 267 20033 20038 1400319 1:CAS:528:DyaK38XlsVGlsbk%3D
14. CA Argmann JY Edwards CG Sawyez, et al. 2005 Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition J Biol Chem 280 22212 22221 15817453 10.1074/jbc.M502761200 1:CAS:528: DC%2BD2MXksl2htro%3D (Pubitemid 40827878)
15. PJ Casey 1995 Protein lipidation in cell signaling Science 268 221 225 7716512 10.1126/science.7716512 1:CAS:528:DyaK2MXltVCitLs%3D
16. Y Kureishi Z Luo I Shiojima, et al. 2000 The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals Nat Med 6 1004 1010 10973320 10.1038/79510 1:CAS:528:DC%2BD3cXmslSjsL0%3D
17. W Sun T-S Lee MJ Zhu, et al. 2006 Statins activate AMP-activated kinase in vitro and in vivo Circulation 114 2655 2662 17116771 10.1161/CIRCULATIONAHA. 106.630194 1:CAS:528:DC%2BD28Xht1Ohu7zP (Pubitemid 44967349)
18. X Li Y Han W Pang, et al. 2008 AMP-activated protein kinase promotes the differentiation of endothelial progenitor cells via eNOS-derived NO Arterio Thromb Vasc Biol. 28 1789 1795 10.1161/ATVBAHA.108.172452
19. U Laufs V La Fata J Plutzky, et al. 1998 Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors Circulation 97 1129 1135 9537338 1:CAS:528:DyaK1cXisVWmsrY%3D (Pubitemid 28152885)
20. U Laufs V La Fata JK Liao 1997 Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase J Biol Chem 272 31725 31729 9395516 10.1074/jbc.272.50. 31725 1:CAS:528:DyaK2sXotVSkurY%3D (Pubitemid 28013321)
21. M Yano T Matsumura T Senokuchi, et al. 2007 Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages Circ Res 100 1442 1451 17463321 10.1161/01.RES. 0000268411.49545.9c 1:CAS:528:DC%2BD2sXltl2ntr4%3D (Pubitemid 46834756)
22. K Sugamura S Sugiyama Y Matsuzawa, et al. 2008 Benefit of adding pioglitazone to successful statin therapy in nondiabetic patients with coronary artery disease Circ J 72 1193 1197 18577834 10.1253/circj.72.1193 1:CAS:528:DC%2BD1cXovFelt78%3D (Pubitemid 351957091)
23. I Zelvyte R Dominaitiene M Crisby S Janciauskiene 2002 Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro Pharmacol Res 45 147 154 11846628 10.1006/phrs.2001.0922 1:CAS:528:DC%2BD38XhtFCltLc%3D (Pubitemid 35425654)
24. R Corti JI Osende JT Fallon, et al. 2004 The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging J Am Coll Cardiol 43 464 473 15013132 10.1016/j.jacc.2003.08.048 1:CAS:528:DC%2BD2cXitV2jtbY%3D (Pubitemid 38167710)
25. Qin W, Lu Y, Zhan C, et al. Simvastatin suppresses apoptosis in vulnerable atherosclerotic plaques through regulating the expression of p53, Bcl-2 and Bcl-xL. Cardiovasc Drugs Ther 2012;26: this issue
26. M Aikawa E Rabkin S Sugiyama, et al. 2001 An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro Circulation 103 276 283 11208689 1:CAS:528:DC%2BD3MXhtFaitr4%3D (Pubitemid 32095415)
27. M Crisby G Nordin-Fredriksson PK Shah, et al. 2001 Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization Circulation 103 926 933 11181465 1:CAS:528: DC%2BD3MXit1Cru70%3D (Pubitemid 32183796)
28. KK Koh 2000 Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability Cardiovasc Res 47 648 657 10974215 10.1016/S0008-6363(00)00146-2 1:CAS:528:DC%2BD3cXmt1WqtLk%3D
29. PM Ridker E Danielson FA Fonseca, et al. 2009 Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial Lancet 373 1175 1182 19329177 10.1016/S0140-6736(09)60447-5 1:CAS:528:DC%2BD1MXktV2gsL8%3D
30. T Takayama T Hiro M Yamagishi, et al. 2009 Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: Multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS) Circ J 73 2110 2117 19801853 10.1253/circj.CJ-09-0358 1:CAS:528:DC%2BD1MXhsVKgsbzE